Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1986 1
1987 1
1990 3
1991 1
1992 3
1993 2
1995 1
1996 3
1997 1
1998 2
1999 2
2000 1
2001 5
2002 3
2003 3
2004 2
2005 2
2006 2
2007 2
2008 5
2009 5
2010 7
2011 8
2012 8
2013 5
2014 2
2015 8
2016 8
2017 8
2018 14
2019 8
2020 10
2021 11
2022 8
2023 11
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

146 results

Results by year

Filters applied: . Clear all
Page 1
Myelodysplastic syndromes: 2023 update on diagnosis, risk-stratification, and management.
Garcia-Manero G. Garcia-Manero G. Am J Hematol. 2023 Aug;98(8):1307-1325. doi: 10.1002/ajh.26984. Epub 2023 Jun 8. Am J Hematol. 2023. PMID: 37288607 Review.
DISEASE OVERVIEW: The myelodysplastic syndromes (MDS) are a very heterogeneous group of myeloid disorders characterized by peripheral blood cytopenias and increased risk of transformation to acute myelogenous leukemia (AML). ...At the pre …
DISEASE OVERVIEW: The myelodysplastic syndromes (MDS) are a very heterogeneous group of myeloid disorders charac …
MYC as a target for cancer treatment.
Duffy MJ, O'Grady S, Tang M, Crown J. Duffy MJ, et al. Cancer Treat Rev. 2021 Mar;94:102154. doi: 10.1016/j.ctrv.2021.102154. Epub 2021 Jan 19. Cancer Treat Rev. 2021. PMID: 33524794 Free article. Review.
Because of its high prevalence of deregulation and its causal role in cancer formation, maintenance and progression, targeting MYC is theoretically an attractive strategy for treating cancer. ...Based on its broad efficacy and limited toxicity, OmoMYC is currently being de …
Because of its high prevalence of deregulation and its causal role in cancer formation, maintenance and progression, targeting MYC is …
Myelodysplastic syndromes: 2021 update on diagnosis, risk stratification and management.
Garcia-Manero G, Chien KS, Montalban-Bravo G. Garcia-Manero G, et al. Am J Hematol. 2020 Nov;95(11):1399-1420. doi: 10.1002/ajh.25950. Am J Hematol. 2020. PMID: 32744763 Free article. Review.
DISEASE OVERVIEW: The myelodysplastic syndromes (MDS) are a very heterogeneous group of myeloid disorders characterized by peripheral blood cytopenias and increased risk of transformation to acute myelogenous leukemia (AML). Myelodyspl …
DISEASE OVERVIEW: The myelodysplastic syndromes (MDS) are a very heterogeneous group of myeloid disorders charac …
Acute myeloid leukemia: Treatment and research outlook for 2021 and the MD Anderson approach.
Kantarjian HM, Kadia TM, DiNardo CD, Welch MA, Ravandi F. Kantarjian HM, et al. Cancer. 2021 Apr 15;127(8):1186-1207. doi: 10.1002/cncr.33477. Epub 2021 Mar 18. Cancer. 2021. PMID: 33734442 Free article. Review.
The unraveling of the pathophysiology of acute myeloid leukemia (AML) has resulted in rapid translation of the information into clinical practice. ...LAY SUMMARY: Ongoing research in acute myeloid leukemia (AML) is progressing rapi …
The unraveling of the pathophysiology of acute myeloid leukemia (AML) has resulted in rapid translation of the informat …
Severe aplastic anemia: allogeneic bone marrow transplantation as first-line treatment.
Georges GE, Doney K, Storb R. Georges GE, et al. Blood Adv. 2018 Aug 14;2(15):2020-2028. doi: 10.1182/bloodadvances.2018021162. Blood Adv. 2018. PMID: 30108110 Free PMC article. Review.
Treatment of severe aplastic anemia has improved significantly over the past 4 decades. This review will summarize the key areas of progress in the use of allogeneic hematopoietic cell transplantation and nontransplant immunosuppressive therapy (IST) for the treatme …
Treatment of severe aplastic anemia has improved significantly over the past 4 decades. This review will summarize the key areas of progr …
Chronic myelomonocytic leukemia diagnosis and management.
Chan O, Renneville A, Padron E. Chan O, et al. Leukemia. 2021 Jun;35(6):1552-1562. doi: 10.1038/s41375-021-01207-3. Epub 2021 Mar 13. Leukemia. 2021. PMID: 33714974 Review.
Chronic myelomonocytic leukemia (CMML) is a rare, heterogeneous myeloid malignancy classified as a myelodysplastic syndromes/myeloproliferative neoplasm (MDS/MPN) overlap syndrome by the World Health Organization (WHO). ...Outcomes vary substant …
Chronic myelomonocytic leukemia (CMML) is a rare, heterogeneous myeloid malignancy classified as a myelodysplastic s …
Molecular Pathogenesis and Treatment of Myelodysplastic Syndromes.
Nakajima H. Nakajima H. Intern Med. 2021 Jan 1;60(1):15-23. doi: 10.2169/internalmedicine.4214-19. Epub 2020 Feb 1. Intern Med. 2021. PMID: 32009100 Free PMC article.
Myelodysplastic syndromes (MDS) are clonal hematological disorders arising from hematopoietic stem cells that have accumulated various genetic abnormalities. MDS are heterogeneous in nature but uniformly characterized by chronic and progressive cytopenia from …
Myelodysplastic syndromes (MDS) are clonal hematological disorders arising from hematopoietic stem cells that have accumulated …
Management of patients with lower-risk myelodysplastic syndromes.
Brunner AM, Leitch HA, van de Loosdrecht AA, Bonadies N. Brunner AM, et al. Blood Cancer J. 2022 Dec 14;12(12):166. doi: 10.1038/s41408-022-00765-8. Blood Cancer J. 2022. PMID: 36517487 Free PMC article. Review.
Myelodysplastic syndromes (MDS) are a heterogeneous group of hematopoietic stem cell disorders characterized by ineffective hematopoiesis with abnormal blood cell development (dysplasia) leading to cytopenias and an increased risk for progression to acute …
Myelodysplastic syndromes (MDS) are a heterogeneous group of hematopoietic stem cell disorders characterized by ineffective he …
Myelodysplastic syndromes current treatment algorithm 2018.
Steensma DP. Steensma DP. Blood Cancer J. 2018 May 24;8(5):47. doi: 10.1038/s41408-018-0085-4. Blood Cancer J. 2018. PMID: 29795386 Free PMC article. Review.
Myelodysplastic syndromes (MDS) include a group of clonal myeloid neoplasms characterized by cytopenias due to ineffective hematopoiesis, abnormal blood and marrow cell morphology, and a risk of clonal evolution and progression to acute myelo …
Myelodysplastic syndromes (MDS) include a group of clonal myeloid neoplasms characterized by cytopenias due to ineffect …
Novel Approaches and Future Directions in Myelodysplastic Syndrome Treatment.
Bewersdorf JP, Xie Z, Zeidan AM. Bewersdorf JP, et al. Cancer J. 2023 May-Jun 01;29(3):195-202. doi: 10.1097/PPO.0000000000000658. Cancer J. 2023. PMID: 37195776
Myelodysplastic syndromes/neoplasms (MDSs) constitute a heterogeneous group of clonal disorders that are clinically characterized by dysplastic changes in multiple hematopoietic lineages, cytopenias, and a variable risk of progression to acute myelo …
Myelodysplastic syndromes/neoplasms (MDSs) constitute a heterogeneous group of clonal disorders that are clinically characteri …
146 results